Greater incidence of depression with hypnotic use than with placebo
Related Articles
- FDA APPROVES ILOPERIDONE FOR THE TREATMENT OF SCHIZOPHRENIA. Naccari, Christopher // Primary Psychiatry;Jun2009, Vol. 16 Issue 6, p12
The article reports on the approval of iloperidone for the treatment of schizophrenia in adults by the U.S. Food and Drug Administration (FDA). The results of two short-term, placebo-controlled clinical trials were used by FDA as the basis of the approval. Dizziness, dry mouth and fatigue were...
- Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety. Dell'Utri, Chiara; Digesu, G.; Bhide, Alka; Khullar, Vik // International Urogynecology Journal;Oct2012, Vol. 23 Issue 10, p1337
Introduction and hypothesis: This is a systematic review of clinical data assessing the safety, efficacy and tolerability of fesoterodine in randomised control trials (RCTs) in the treatment of overactive bladder (OAB). Methods: We performed a MEDLINE literature search of articles published...
- US FDA reviewing safety of ezetimibe/simvastatin. // Reactions Weekly;8/30/2008, Issue 1217, p2
The article reports on the safety review by the U.S. Food and Drug Administration (FDA) of ezetimibe (Vytorin) and simvastatin after receiving a report from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial about a possible association between ezetimibe use and increased cancer risk....
- FDA Approves Cimzia for Crohn's Disease. // Bioworld Week;4/28/2008, Vol. 16 Issue 17, p4
The article reports on the approval of UCB SA's Cimzia (certolizumab pegol), a PEGylated antitumor- necrosis-factor (TNF)-alpha antibody by the Food & Drug Administration (FDA) for Crohn's disease. It states that datum from Phase III pivotal studies presented patients with moderate to severe...
- Abilify Approved for Acute Bipolar Mania. Stanwood, Karen G. // Journal of Psychosocial Nursing & Mental Health Services;Dec2004, Vol. 42 Issue 12, p32
The article reports on the approval of Abilify for the treatment of acute bipolar mania by the U.S. Food and Drug Administration. the approval was based on positive results from two placebo-controlled, 3-week trials of 516 hospitalized patients with bipolar I disorder. The drug's common side...
- FDA advisers wary of expanding quetiapine use. Traynor, Kate // American Journal of Health-System Pharmacy;5/15/2009, Vol. 66 Issue 10, p880
The article discusses the concern of the U.S. Food and Drugs Administration (FDA) advisers on the expanded use of quetiapine fumarate. It mentions that advisers have agreed that it should not be used as a first line monotherapy for major depressive disorder (MDD) since its long term risk has not...
- Questions still linger about Accutane, depression. Gillete, Bill // Dermatology Times;Jan2005, Vol. 26 Issue 1, p15
The article reports that questions continue to linger about Accutane and its possible link to depression, even as the U.S. Food and Drug Administration prepares to tighten monitoring of the controversial acne drug and its generic equivalents. The drug can caused severe birth defects and has been...
- Smoking Cessation and Psychiatric Effects. // Infectious Disease Alert;Sep2009 Pharmacology Watch, p2
The article offers advice from the U.S. Food and Drug Administration (FDA) regarding smoking cessation drugs varenicline (Chantix) and bupropion (Zyban, Wellbutrin) and their side effects. The FDA required a new box warnings emphasizing the risk of serious neuropsychiatric symptoms associated...
- FDA APPROVES DULOXETINE FOR MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER. Lanche, Michelisa // CNS Spectrums: The International Journal of Neuropsychiatric Med;Jan2008, Vol. 13 Issue 1, p23
The article reports that the U.S. Food and Drug Administration has approved duloxetine for the maintenance treatment of major depressive disorder (MDD) in adults of, or above 18 years of age. It reports that during the acute phase, the most frequently reported side effect was, nausea. Duloxetine...